The Leading Industry Voice on Biosecurity
The Alliance for Biosecurity is a coalition of biopharmaceutical companies and laboratory partners advancing the public-private partnerships that develop, produce, and stockpile the medical countermeasures our nation depends on.
What We Do
The Alliance for Biosecurity helps to identify threats facing our nation and provides solutions by building and strengthening the relationship between government and the biopharmaceutical industry.
Learn MoreAdvancing America’s biosecurity through partnership, preparedness, and policy.
For sustained, bipartisan federal investment in the programs that strengthen America’s biodefense: BARDA, ASPR, Project BioShield, Pandemic Influenza, and the SNS.
Public-private partnerships that accelerate innovation, streamline procurement, and close readiness gaps across the CBRN threat landscape.
The development and stockpiling of next-generation countermeasures—from antibacterials and antivirals to urgently needed antifungal agents.
A coordinated, forward-looking national biodefense strategy aligned with a unified, whole-of-government framework.
With Congress, the Administration, and federal agencies to shape biodefense policy that keeps pace with evolving threats.
Policymakers, the press, and the public on the importance of sustained preparedness and domestic MCM development.
Who We Are
The Alliance for Biosecurity is a coalition of biopharmaceutical companies and laboratory and academic partners that promotes a strong public-private partnership to ensure medical countermeasures are available to protect public health and enhance national health security.
Our members are among the U.S. Government’s key medical countermeasure developers—the companies whose vaccines, therapeutics, and diagnostics defend Americans, at home and abroad, against deadly biological threats.
Learn more about the AllianceFY 2027 Appropriations Request
The Alliance for Biosecurity urges Congress to build on its longstanding bipartisan, bicameral support and fully resource the medical countermeasure programs that underpin national security and public health preparedness.
| HHS Program (in $ millions) | PHEMCE 2023–27 Multi-Year Budget |
FY26 Enacted |
President’s FY27 Request |
FY27 Alliance Request |
|---|---|---|---|---|
| BARDA — Advanced R&D | $8,851 | $1,050 | $654 | $1,400 |
| Project BioShield (SRF) | $1,630 | $850 | $725 | $1,000 |
| Pandemic Influenza Preparedness | $1,913 | $308 | $308 | $410 |
| Strategic National Stockpile | $1,588 | $1,000 | $938 | $1,588 |
Add your company’s voice to the leading coalition shaping America’s biodefense agenda—with direct access to the policymakers who fund it.